University of New Mexico

UNM Digital Repository
Pediatrics Research and Scholarship

Pediatrics

12-1-2020

Breast Cancer Screening Among Medically Underserved Women
in New Mexico: Potential for Lower Recall Rates with Digital
Breast Tomosynthesis
Martha T Manda-Mapalo
Stephanie G Fine
Sarah Safadi
Ji-Hyun Lee
Ruofei Du

See next page for additional authors

Follow this and additional works at: https://digitalrepository.unm.edu/peds_pubs

Authors
Martha T Manda-Mapalo, Stephanie G Fine, Sarah Safadi, Ji-Hyun Lee, Ruofei Du, Andrew L Sussman,
Shiraz Mishra, Reed G Selwyn, Jennifer L Saline, Wendy L Hine, and Ursa A Brown-Glaberman

JOURNAL OF WOMEN’S HEALTH
Volume 29, Number 12, 2020
ª Mary Ann Liebert, Inc.
DOI: 10.1089/jwh.2020.8402

Breast Cancer Screening Among Medically Underserved
Women in New Mexico:
Potential for Lower Recall Rates
with Digital Breast Tomosynthesis
Martha T. Manda-Mapalo, MBChB,1 Stephanie G. Fine, MD, FACS,2 Sarah Safadi, MD,3
Ji-Hyun Lee, DrPH, MS,4 Ruofei Du, PhD,5,6 Andrew L. Sussman, PhD, MCRP,7
Shiraz Mishra, MBBS, PhD,8 Reed G. Selwyn, PhD, DABR,9 Jennifer L. Saline, MD,9
Wendy L. Hine, PhD,10 and Ursa A. Brown-Glaberman, MD1

Abstract

Introduction: Digital breast tomosynthesis (DBT) may decrease recall rates (RRs) and improve positive
predictive values (PPVs) and cancer detection rates (CDRs) versus full-field digital mammography (FFDM).
The value of DBT has not been assessed in New Mexico’s rural and minority population. Objectives of this
study were to compare RRs, CDRs, and PPVs using FFDM+DBT versus FFDM in screening mammograms at
the University of New Mexico between 2013 and 2016 and to qualitatively evaluate patient decision-making
regarding DBT.
Materials and Methods: RRs, CDRs, and PPVs with 95% confidence intervals and relative risk were calculated
from 35,147 mammograms. The association between relative risk and mammography approach was tested using
Pearson’s chi-square test. Twenty women undergoing screening were interviewed for qualitative evaluation of
decision-making.
Results: From 2013 to 2016, RRs were 8.4% and 11.1% for FFDM+DBT and FFDM, respectively. The
difference in RRs became more pronounced with time. No significant difference was observed in PPVs or
CDRs. Qualitative interviews revealed that the majority had limited prior knowledge of DBT and relied on
provider recommendations.
Conclusion: In New Mexico women undergoing screening mammography, a 30% relative risk reduction in RRs
was observed with FFDM+DBT. Qualitative interviews suggest that women are aware of and receptive to DBT,
assuming adequate educational support. Clinical Trials.gov ID: NCT03979729.
Keywords: medically underserved women, digital breast tomosynthesis, breast cancer screening, recall rate
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Introduction

D

igital breast tomosynthesis (DBT), or threedimensional (3D) mammography, involves the acquisition and reconstruction of multiple, thin-slice, tomographic
projection images of the breast. It is performed in conjunction
with a separate two-dimensional (2D) image or a synthetic
reconstruction 2D image (denoted as FFDM+DBT hereafter).
DBT has the potential to improve breast imaging when
compared with 2D full-field digital mammography (FFDM)
by providing a series of images through the breast. This reduces tissue overlap and assists in discrimination between
normal tissue structures and malignancy detection. As a
result, DBT may improve sensitivity and specificity of
screening mammography and thereby reduce unnecessary
recalls.1 In addition to the cancer detection rate (CDR), recall
rate (RR), which is defined as the percentage of screening
mammogram studies that require further diagnostic evaluation,2 is a metric of particular interest with regard to breast
cancer screening. A concern related to DBT is the cost at a
population level when its use is generalized to all women
undergoing breast cancer screening. Despite increasing
worldwide adoption of DBT, there is not yet a consensus
regarding approved indications, management guidelines, and
evidence-based application of the Breast Imaging Reporting
and Data System.3
New Mexico has a large proportion of ethnic/racial minorities and widespread language barriers (a third of the
population speaks a language other than English at home).4
Nearly 25% of the population lives in a rural area.5 Of the
2 million people living in New Mexico, according to the U.S.
Census Bureau estimates, 48.5% self-identified as Hispanic,
37.8% self-identified as White, and 10.1% self-identified as
American Indian.5 The estimated percentages of women,
aged 50–74 years, who had had a mammogram within the
previous 2 years, by race/ethnicity, in New Mexico in 2016
were as follows: 75.3% Hispanic, 67.7% Black/African
American, and 74.8% American Indian women compared
with 70% non-Hispanic White women.6 Overall, New
Mexico ranked 50th in up-to-date mammography in women
45 years and older in 2018.7 According to the 2017 U.S.
Census Bureau, New Mexico was tied for second place with
the highest percentage of people living below the poverty line
at 19.7% (U.S. Census Bureau, 2017). Factors that have been
associated with low mammography screening rates include
low socioeconomic status, belonging to a racial/ethnic minority, and living in a rural area.8,9
RR compliance is also known to be affected by race and
ethnicity, with delayed presentation common in Hispanic and
African American women compared with non-Hispanic
Whites.10 The patient cost associated with recall after a false
positive screening mammogram is a financial hardship that
may disproportionally affect medically underserved women.
This cost has been estimated at $138/recall, and although
insurance covers part of the cost, there are other intangible
costs involved, including travel, concerns regarding child
care, and work absenteeism, as well as associated anxiety.11
The value of DBT as a method for breast cancer screening
has not been assessed in unique patient populations such as
ours. We hypothesize that DBT is associated with a reduction
in RR compared with FFDM in the population of minority
and medically underserved women who characterize our
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state. To evaluate this, we retrospectively analyzed 35,147
screening mammograms conducted at the University of New
Mexico (UNM) between 2013 and 2016 for RRs. In addition,
we analyzed two other key clinical outcomes of interest related to the screening mammogram, positive predictive
value (PPV) and CDR. Additionally, we sought to characterize the general knowledge and perspectives of medically
underinsured women toward DBT – FFDM. We conducted
a qualitative evaluation of patient perspectives on factors
influencing uptake and decision-making regarding DBT to
better understand the complexities of decision-making between FFDM+DBT and FFDM among Medicaid-eligible
women in our breast cancer screening population.
Materials and Methods

This study was approved by the UNM Institutional Review
Board and was compliant with the Health Insurance Portability and Accountability Act (HIPAA).
Study population

Women undergoing screening mammography in the UNM
Department of Radiology are referred predominantly from
our primary care, gynecology, and cancer center clinics.
Demographic data for the women undergoing screening
mammography in this study were not available. However, as
representative of our referral base, the University of New
Mexico Comprehensive Cancer Center (UNM CCC) sees
1,884 new cancer diagnoses yearly. Hispanic patients account for 639 (33%) new cases per year, while American
Indians account for an additional 127 cases (7%). Approximately 48% of the cancer patients seen at the UNM CCC
reside outside Bernalillo County (where UNM CCC is located). Twenty percent of UNM CCC patients travel >100
miles to receive care compared with 9% of the national
average for academic medical centers as per the Commission
on Cancer.
Quantitative mammogram evaluation measurements

We retrospectively analyzed 35,147 screening mammograms conducted at the UNM between 2013 and 2016. The
primary quantitative endpoints were RR, PPV, and CDR for
DBT+FFDM and FFDM. RR is defined as the number of
women recalled for additional imaging after the screening
mammogram divided by the total number of women
screened. PPV is defined as the percentage of all positive
screening examinations that result in a tissue diagnosis of
cancer within 1 year. CDR is defined as the number of cancer
cases detected divided by 1,000 persons screened. Mammography data were collected from the UNM Hospital
Mammography Tracking and Reporting System (PenRad
Technologies, Inc., Buffalo, MN). Data were aggregated for
FFDM and FFDM+DBT examinations performed between
January 1, 2013, and December 31, 2016. The logic for the
query and derivation of the resulting information was developed by PenRad from their pathology summary report.
The selection logic for that query was modified to restrict the
results to women whose age at the time of the examination
was 40 years or older. Abstracted data elements are detailed
in Table 1.
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Table 1. Abstracted Data Elements
No. of screening cases or select mammogram type
No. of screening cases, BI-RADS categories 0, 4, or 5
No. of biopsy pathologies that were malignant
No. of biopsy pathologies that were benign
No. of cases from BI-RADS 4 and 5 lost, refused, etc.
No. of ductal carcinoma in situ
No. of true positives
No. of false positives
Positive predictive value
Cancer detection rate
% recall (recall rate)
BI-RADS, Breast Imaging-Reporting and Data System.

Qualitative evaluation of patient
perspective measurement

We conducted qualitative interviews with women who had
undergone recent mammographic screening. We purposefully sampled women who matched eligibility requirements
for either Medicaid or the Breast and Cervical Cancer Early
Detection Program. We sought to achieve sampling parity between women who had selected either FFDM or
FFDM+DBT screening. The purpose of these interviews was
to identify women’s general experiences of barriers and/or
facilitators to mammography, explore knowledge/awareness
of DBT, assess decisional influences impacting receptivity to DBT, and identify concerns about DBT and preferred
informational needs.
We developed a semistructured interview guide based on
the domains above. Women were recruited using both clinicbased and telephone interview strategies. A research team
member identified and approached women meeting eligibility requirements following completion of their mammogram.
If interested, the interview was conducted at that time in a
private setting at the clinic or scheduled for a subsequent
phone interview. Additionally, we reviewed a list of completed mammograms and research staff contacted women by
phone to confirm eligibility and assess interest in participation. All interviews were audio recorded for subsequent
transcription and analysis. Women received a $50 merchandise card for their participation.
Interviews continued until we reached data saturation, a
standard criterion used in qualitative research to determine
the sample size.12 Data saturation occurs when new data are
redundant and the research team concludes that maximum
variation has been reached with regard to relevant themes.
Completed transcripts were reviewed by two members of
the research team and a coding template was developed based
on iterative readings and reaching consensus on major
themes. Once the coding template was finalized, the interviews were imported into NVivo10, a qualitative data analysis software program that facilitates coding and analytic
queries. The analysts generated coding reports and data
summaries used to organize key findings.
We interviewed a total of 20 women. The initial number
sought was 40 women; however, data saturation was attained
with 20. Of these, ten women received FFDM, 9 women
received FFDM+DBT, and one woman was unsure of the
mammogram type received. The average age was 57.6 years
and all but two participants lived within 20 miles of the
screening facility. Last, all participants were Medicaid re-

cipients. To ensure that all participants had a similar baseline
of knowledge from which to examine perceptions about test
characteristics, including the RR, radiation exposure, and
cost, we reviewed an informational brochure, developed by
Department of Radiology clinicians, with all interviewees at
the midpoint of the interview.
Statistical analysis

The 95% confidence interval (CI) for a rate was obtained
under the exact binomial distribution using the Clopper–
Pearson method. The relative risk, defined as the ratio of two
RRs (i.e., FFDM+DBT divided by FFDM), was used as the
primary measure in our study to evaluate if FFDM+DBT
reduces the RR compared with FFDM in our minority and
medically underserved population. The 95% CI for relative
risk for each year was calculated using the standard Wald
asymptotic method. The association between relative risk and
the mammography approach within each year was tested
using Pearson’s chi-square test. The Cochran–Mantel–
Haenszel method was used to calculate a weighted average
of the relative risk across the years and also to assess the
significance of the association controlling the factor of the
years.
Results
Quantitative mammogram evaluation

The percentage of DBT+FFDM mammograms performed
increased over the study period from less than 10% (6.8% in
2013) DBT+FFDM examinations to 66.9% of total mammograms in 2016 (Table 2). Table 3 details RRs, PPVs, and
CDRs over the study period.
Recall rate. RRs and relative risk of recall are summarized in Table 4. Over the 4-year period, RRs were 8.4% and
11.1% for FFDM+DBT and FFDM, respectively. The difference in RRs became more pronounced with time. This
difference was statistically significant in the year 2016, at
8.1% versus 14% (RR: 0.58, 95% CI 0.51–0.66, p < 0.001).
Across 4 years, the relative risk of a call back was 30% lower
with FFDM+DBT (RR: 0.7, 95% CI 0.64–0.77).
Positive predictive value. The PPV for 2013–2016 was
6.1% versus 4.8% for FFDM+DBT and FFDM, respectively
(RR 1.46, 95% CI 0.97–2.19, p = 0.07). PPVs are detailed by
year and in total in Table 3.

Table 2. The Number (%) of Mammograms, by Type,
Performed at the UNM CCC by Year
Year
2013
2014
2015
2016
Total

FFDM+DBT, N (%)
680
540
837
5431
7,488

(6.8
(6.5)
(9.7)
(66.9)
(21.3)

FFDM, N (%)
9,387
7,815
7,771
2,686
27,659

(93.2)
(93.5)
(90.3)
(33.1)
(78.7)

UNM CCC, University of New Mexico Comprehensive Cancer
Center.
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Table 3. The Recall Rate (%), PPV (%), and Cancer Detection Rate (%) with 95% CI
for Mammograms, by Type, Performed at the UNM CCC by Year
Recall rate % (95% CI)
Year
2013
2014
2015
2016
Total

FFDM+DBT

Positive predictive value % (95% CI)

FFDM

10.15%
10.90%
(7.98%–12.67%) (10.27%–11.55%)
7.96%
10.19%
(5.82%–10.58%) (9.52%–10.88%)
9.08%
11.14%
(7.22%–11.23%) (10.45%–11.86%)
8.10%
14.00%
(7.39%–8.86%) (12.71%–15.37%)
8.39%
11.07%
(7.77%–9.04%) (10.7%–11.44%)

Cancer detection rate % (95% CI)

FFDM+DBT

FFDM

FFDM+DBT

FFDM

10.14%
(4.18%–19.79%)
6.98%
(1.46%–19.06%)
5.26%
(1.45%–12.93%)
5.45%
(3.53%–8.01%)
6.05%
(4.32%–8.21%)

4.99%
(3.73%–6.5%)
5.53%
(4.04%–7.35%)
4.27%
(3.03%–5.84%)
3.99%
(2.25%–6.49%)
4.80%
(4.07%–5.62%)

1.03%
(0.41%–2.11%)
0.56%
(0.11%–1.61%)
0.48%
(0.13%–1.22%)
0.44%
(0.28%–0.66%)
0.51%
(0.36%–0.7%)

0.54%
(0.4%–0.71%)
0.56%
(0.41%–0.76%)
0.48%
(0.34%–0.66%)
0.56%
(0.31%–0.92%)
0.53%
(0.45%–0.62%)

CI, confidence interval; DBT, digital breast tomosynthesis; FFDM, full-field digital mammography; PPV, positive predictive value.

Cancer detection rate. The CDR for 2013–2016 was
observed as 5.1 and 5.3 cases per 1,000 screening events for
FFDM+DBT and FFDM, respectively, with no statistically
significant difference observed. CDRs are detailed by year
and in total in Table 3.
Qualitative interview results

Overall, participants in both FFDM and FFDM+DBT groups
believed that breast cancer screening is a high priority and they
strongly endorsed the general merits of the test. The vast majority of women (N = 18) indicated that they seek to obtain an
annual mammogram, although lapses or variations in insurance
coverage may impact screening follow-through. In terms of
decisional influences for routine annual screening recommendations, women identified the importance of their primary care
provider’s recommendation as the most salient factor.
The majority of women (N = 14) had some degree of
awareness with respect to FFDM+DBT through advertisements, friends/family, or a health care provider. Despite the
lack of definitive clinical evidence for FFDM+DBT, women
commonly reported a perspective that this screening test is
superior, mostly attributable to the belief that the images are
clearer. When asked whether they would be willing to pay an
additional amount out of pocket for FFDM+DBT, all participants indicated this would be a financial hardship. However, consistent with the predominant view that FFDM+DBT
is superior, over half of the women (N = 11) noted that they
would defer to the strength of their provider’s recommendation. If this recommendation was strong, they would be
willing to sacrifice other necessities to secure additional
funds to cover the cost. Among the remaining women (N = 9),

financial hardship was cited as the primary reason for not
undergoing FFDM+DBT if an additional copay is required
(see Appendix Table 1 for individual interview quotes).
In terms of the potential for DBT to reduce the RR, virtually
all participants supported the benefits of minimizing return
visits. With regard to radiation, there were mixed views about
the slight increase in radiation exposure with FFDM+DBT.
Half of the women (N = 10) indicated that they would like to
have more specific information about the implications of this
increased radiation, although all believed that the superior
accuracy of the test warranted this slight risk.
Discussion

In our New Mexico population, women undergoing screening mammography between 2013 and 2016 had a significant
30% relative risk reduction in the RR with the use of
FFDM+DBT compared with conventional FFDM. This difference was most pronounced in the last year of the study.
Our finding of reduced RRs in the FFDM+DBT arm is in line
with findings of the Italian Screening with Tomosynthesis Or
standard Mammography (STORM) trial and the Oslo Tomosynthesis Screening Trial (OTST).13,14 Our study did not
show an increase in CDR, contrary to findings of the STORM
trial and Malmo and Oslo trials.
Similar to our findings, DiPrete et al. observed an increased RR for FFDM as years of experience with
FFDM+DBT increased. This increase in RR approached
statistical significance in their study. This is thought to be
due to a decrease in confidence by the radiologist when interpreting FFDM after seeing improved visualization of
cancers on FFDM+DBT. Simultaneous viewing of DBT

Table 4. Recall Rate, Digital Breast Tomosynthesis (FFDM+DBT) Versus FFDM, 2013–2016
Year

FFDM+DBT vs. FFDM

2013
2014
2015
2016
2013–2016

10.15% vs. 10.90%
7.96% vs. 10.19%
9.08% vs. 11.14%
8.10% vs. 14.00%
8.39% vs. 11.07%

a
Relative risk adjusted by the CMH method.
CMH, Cochran–Mantel–Haenszel.

Relative riska (95% CI)

p-Value for relative risk = 1

0.931 (0.739–1.173)
0.782 (0.583–1.049)
0.815 (0.652–1.019)
0.579 (0.508–0.659)
0.699a (0.635–0.768)

0.5431
0.0965
0.0692
<0.0001
<0.0001
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and FFDM images could simply demonstrate the lack of visualization of cancer findings on FFDM alone and increase
diagnostic uncertainty. The increased RR with FFDM (2016)
in our study seems to be explained by this effect, but the exact
reason is unknown.
Our qualitative interview data found that the majority of
women had prior knowledge of FFDM+DBT, although
they were not aware of the specific differences between the
tests other than a general sense of advanced technology being utilized. We purposefully sampled Medicaid-eligible
participants to better understand the complexities of decisionmaking between FFDM+DBT and FFDM among underserved
women. Not surprisingly, all women noted that cost was a
major consideration if FFDM+DBT was not covered through
Medicaid. However, given that most of the participants
viewed this as a superior test, they anticipated basing a final
decision on the strength of their provider’s recommendation. If
their health care provider strongly encouraged the test, most
women agreed that they would find the resources to pay even if
it meant sacrificing another necessity. Last, despite awareness
of the slight increase in radiation exposure for FFDM+DBT,
all participants indicated receptivity to this screening test in
the future; however, most indicated a desire to obtain further
information about this risk.
Several large population-based studies have been conducted internationally regarding the role of DBT in comparison with FFDM as a method for breast cancer screening.
These include the Italian STORM trial, which demonstrated
an increase in CDR with DBT of 2.7 cancers per 1,000
screens over FFDM and resulted in fewer false positive recalls at 1.0% versus 2.0% ( p < 0.0001).13 The Swedish
Malmo Breast Tomosynthesis Screening Trial compared
one-view DBT with two-view digital mammography in
14,851 women and demonstrated that sensitivity with regard
to breast cancer detection was higher for DBT at 81% versus
60.4%, with a slightly lower specificity than digital mammography (97.2% vs. 98.1%). Cancer detection was higher in
the DBT arm by 2.2/1,000 women screened over the digital
mammography arm. Interestingly, the RR was higher among
women undergoing DBT versus digital mammography with
a 1.1% increase (95% CI 0.8–1.4; p < 0.0001).15 The UK-based
TOMosynthesis with digital MammographY (TOMMY) trial
also showed significantly increased specificity for FFDM+DBT
and DBT+synthetic FFDM compared with FFDM, with increases observed in all subgroups of breast density and across
all age groups.16 In the recently published OTST, there was a
significant increase in specificity (97.5% vs. 96.4%) and
CDRs per 1,000 women screened (9.3 vs. 6.3) in women who
underwent FFDM+DBT screening compared with FFDM
alone ( p < 0.001). The number of recalls per screen-detected
cancer decreased from 6.7 to 3.6 with the addition of DBT
( p < 0.001).14 A meta-analysis of cancer detection and recall
comparing DBT and FFDM found that the pooled incremental increase in CDR for tomosynthesis from all studies
(n = 17) was 1.6 cancers per 1,000 screens (95% CI 1.1–2.0,
p < 0.001, I2 = 36.9%).17 The ongoing US-led Tomosynthesis
Mammographic Imaging Screening Trial, with an expected
enrollment of 164,946 participants and study completion in
2030, is designed to compare the number of advanced cancers
detected with DBT and FFDM.
Strengths of this study include a robust number of subject
examinations, 35,147 in total, which compares favorably
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with the range of study populations reported in other 3D
mammography trials, ranging from 524 to 173,663, with a
median number of *8,000.18 Additionally, this is the first
study to investigate and report qualitative patient perspective
data regarding DBT.
Limitations of this study include the small number of 3D
examinations in the initial transition period, a circumstance
that likely explains the absence of statistically meaningful
reduction in RRs for the first 3 years. Additionally, we were
unable to exclude a potential bias toward unequal cancer
prevalence rates in the two groups given the unavailability of
individualized cancer risk factors. Furthermore, inclusion of
individual demographics associated with our study population
as a whole may have provided additional insight with regard to
which subgroup gained the most benefit from recall reduction.
Future study directions should assess a more robust view of the
true financial impact of DBT on underserved populations.
The findings of this study are pertinent to centers that
similarly serve large numbers of women from minority, rural,
financially constrained, and medically underserved patient populations. The value of FFDM+DBT as a screening
method for breast cancer continues to be evaluated in multiple large population-based studies. However, the results of
this study provide novel and previously unpublished insights
regarding the unique value of incorporating DBT into cancer
care delivery for medically underserved women.
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Appendix

Appendix Table A1. Patient Exemplary Quotes
General views of DBT

DBT decision as contingent
on provider
recommendation
Inability to undergo DBT
if additional payment
is required
Recall rate
Concerns about radiation

‘‘I’m under the assumption that the 3D is a lot better. I always go with the 3D, just because
of the advanced technology.’’
‘‘I think it’s marvelous technology. And I think that in the effort to fight breast cancer, 3D
mammography should be mandatory at least every couple years or every third year just to
make sure certain things are ok.’’
‘‘My health care provider usually does tell me what is necessary.now had my provider felt
that it was something that needed to be addressed immediately (getting a 3D
mammogram), absolutely. I would figure out how to pay for it. I don’t really have a lot for
extras. It would probably end up being one of the bills being put off.’’
‘‘Yeah that’s something I would not be able to do so I wouldn’t be willing to do it.
I wouldn’t be able to cut into my budget because like I said I’m on a fixed income, so for
people like myself, we’re living paycheck to paycheck so there’s no extra money. I would
probably be willing to let all of that go undiagnosed because of my income.’’
‘‘It eliminates that question mark where people have to come back. I think it means a great
deal to any woman.it takes the concern out.’’
‘‘I just want to know if it’s ok or not. And that was my first one (3D mammogram) so I
thought, you know what, it’s ok that this has to be done because it’s more important to
find whatever is wrong.that I need to take it and suck up the radiation to make sure.’’

DBT, digital breast tomosynthesis.

